Skip to main content
. 2014 Jan 6;5(3):667–678. doi: 10.18632/oncotarget.1574

Figure 6. CHEK1 inhibition induces cell death in Docetaxel-resistant cells.

Figure 6

A: Dose-dependent growth of IGR-CaP1 and IGR-CaP1-R100 cells. Cells were treated with various concentrations of CHIR-124 for 48h. Cell proliferation was assessed with WST1. B: Cell proliferation of IGR-CaP1-R100 cells. Cells were treated with 100nM CHIR-124 in the presence or absence of 100nM Docetaxel or with Docetaxel alone during 4 days. Proliferation was assessed using WST1. C: Colony formation assay. IGR-CaP1-R100 cells were seeded in 6-well plates in triplicate and treated with CHIR-124 in the absence or presence of Docetaxel and with Docetaxel alone (100nM). Cells were stained with crystal Violet 3 weeks later. Data are represented as mean ± SD for >3 independent experiments. P value was derived from the two-tailed Student's t test, significantly different (*P<0.05, **P<0.01, ***P<0.001). D: Apoptosis. Cells were treated for 48h with 100nM CHIR-124 in the absence or presence of Docetaxel and with Docetaxel alone (100nM). Apoptosis was assessed using annexinV and propidium iodide staining. Data are represented as mean ± SEM. P value was derived from the two-tailed Student's t test, significantly different (*P<0.05). E: PARP and Caspase-3 cleavage. Cells were treated as in (C). Western-blot analysis was performed using specific antibodies for PARP1, Caspase-3 or β-actin. Ratio of cleaved Caspase-3 vs full-lenght is indicated.